Free Trial
→ Musk’s Project Colossus could mint millionaires (From Brownstone Research) (Ad)tc pixel Free AIM Stock Alerts
NYSE:AIM

AIM ImmunoTech (AIM) Stock Price, News & Analysis

AIM ImmunoTech logo
$2.60 0.00 (0.00%)
Closing price 09/12/2025 03:59 PM Eastern
Extended Trading
$2.59 -0.01 (-0.38%)
As of 09/12/2025 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare

About AIM ImmunoTech Stock (NYSE:AIM)

Key Stats

Today's Range
$2.53
▼
$2.67
50-Day Range
$2.36
▼
$9.36
52-Week Range
$2.33
▼
$36.00
Volume
30,782 shs
Average Volume
64,820 shs
Market Capitalization
$7.04 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$275.00
Consensus Rating
Strong Buy

Company Overview

AIM ImmunoTech Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
30th Percentile Overall Score

AIM MarketRank™: 

AIM ImmunoTech scored higher than 30% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    AIM ImmunoTech has received a consensus rating of Strong Buy. The company's average rating score is 3.50, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Upside Potential

    AIM ImmunoTech has a consensus price target of $275.00, representing about 10,476.9% upside from its current price of $2.60.

  • Amount of Analyst Coverage

    AIM ImmunoTech has only been the subject of 1 research reports in the past 90 days.

  • Read more about AIM ImmunoTech's stock forecast and price target.

  • Earnings Growth

    Earnings for AIM ImmunoTech are expected to decrease in the coming year, from ($0.30) to ($0.35) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of AIM ImmunoTech is -5.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of AIM ImmunoTech is -5.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    AIM ImmunoTech has a P/B Ratio of 13.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    1.61% of the float of AIM ImmunoTech has been sold short.

  • Short Interest Ratio / Days to Cover

    AIM ImmunoTech has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

  • Change versus previous month

  • Dividend Yield

    AIM ImmunoTech does not currently pay a dividend.

  • Dividend Growth

    AIM ImmunoTech does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.61% of the float of AIM ImmunoTech has been sold short.

  • Short Interest Ratio / Days to Cover

    AIM ImmunoTech has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

  • Change versus previous month

  • News Coverage This Week

    MarketBeat has tracked 2 news articles for AIM ImmunoTech this week, compared to 2 articles on an average week.

  • Search Interest

    Only 2 people have searched for AIM on MarketBeat in the last 30 days. This is a decrease of -82% compared to the previous 30 days.

  • MarketBeat Follows

    Only 2 people have added AIM ImmunoTech to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

  • Insider Buying vs. Insider Selling

    In the past three months, AIM ImmunoTech insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 0.02% of the stock of AIM ImmunoTech is held by insiders.

  • Percentage Held by Institutions

    Only 12.02% of the stock of AIM ImmunoTech is held by institutions.

  • Read more about AIM ImmunoTech's insider trading history.
Receive AIM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AIM ImmunoTech and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

AIM Stock News Headlines

Maxim Group Resumes Coverage with a Buy Rating on AIM ImmunoTech (AIM)
September 13 at 10:03 AM  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/AIM/pressreleases/34646955/maxim-group-resumes-coverage-with-a-buy-rating-on-aim-immunotech-aim/
Financial Contrast: AIM ImmunoTech (NYSE:AIM) and Protalix BioTherapeutics (NYSE:PLX)
September 10 at 2:25 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30320391
Trump’s national nightmare is here
Porter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger the biggest forced rotation of capital since World War II. They reveal why Trump is mobilizing America’s tech giants… and name the two stocks most likely to soar as trillions shift behind the scenes.tc pixel
September 13 at 2:00 AM  |  Porter & Company (Ad)
AIM ImmunoTech Highlights Growing Body of Compelling Data of Ampligen for the Treatment of Pancreatic Cancer at Conference in Poland
September 4, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/09/04/3144759/29489/en/aim-immunotech-highlights-growing-body-of-compelling-data-of-ampligen-for-the-treatment-of-pancreatic-cancer-at-conference-in-poland.html
AIM ImmunoTech releases CEO Corner segment
August 22, 2025  |  msn.comhttps://www.msn.com/en-us/money/other/aim-immunotech-releases-ceo-corner-segment/ar-AA1KY4Gn
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
August 21, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/08/21/3137174/29489/en/aim-immunotech-announces-release-of-the-next-ceo-corner-segment.html
AIM ImmunoTech Reports Second Quarter 2025 Financial Results and Provides Corporate Update
August 15, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/08/15/3134244/29489/en/AIM-ImmunoTech-Reports-Second-Quarter-2025-Financial-Results-and-Provides-Corporate-Update.html
Uncovering Potential: AIM ImmunoTech's Earnings Preview
August 14, 2025  |  benzinga.comhttps://www.benzinga.com/insights/earnings/25/08/47097186/uncovering-potential-aim-immunotechs-earnings-preview
See More Headlines

AIM Stock Analysis - Frequently Asked Questions

AIM ImmunoTech's stock was trading at $19.80 on January 1st, 2025. Since then, AIM shares have decreased by 86.9% and is now trading at $2.60.

AIM ImmunoTech Inc. (NYSE:AIM) released its quarterly earnings data on Wednesday, November, 15th. The company reported ($16.00) EPS for the quarter, missing the consensus estimate of ($11.00) by $5.00. The firm earned $0.05 million during the quarter. AIM ImmunoTech had a negative trailing twelve-month return on equity of 421.73% and a negative net margin of 12,594.21%.

AIM ImmunoTech shares reverse split on the morning of Thursday, June 12th 2025.The 1-100 reverse split was announced on Wednesday, June 11th 2025. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, June 11th 2025. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

Top institutional shareholders of AIM ImmunoTech include Corient Private Wealth LLC (1.31%). Insiders that own company stock include Thomas K Equels, Peter W Rodino III, Stewart Appelrouth and Nancy Bryan.
View institutional ownership trends.

Shares of AIM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that AIM ImmunoTech investors own include Inovio Pharmaceuticals (INO), iBio (IBIO), Vaxart (VXRT), Meta Platforms (META), Sorrento Therapeutics (SRNE), NIO (NIO) and T2 Biosystems (TTOO).

Company Calendar

Last Earnings
11/15/2023
Today
9/13/2025
Fiscal Year End
12/31/2025
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NYSE:AIM
CIK
946644
Web
aimimmuno.com
Phone
(352) 448-7797
Fax
215-988-1739
Employees
20
Year Founded
1990

Price Target and Rating

Average Price Target for AIM ImmunoTech
$275.00
High Price Target
$450.00
Low Price Target
$100.00
Potential Upside/Downside
+10,476.9%
Consensus Rating
Strong Buy
Rating Score (0-4)
3.50
Research Coverage
2 Analysts

Profitability

EPS (Trailing Twelve Months)
($24.68)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$28.96 million
Net Margins
-12,594.21%
Pretax Margin
-12,594.21%
Return on Equity
-421.73%
Return on Assets
-147.54%

Debt

Debt-to-Equity Ratio
0.05
Current Ratio
0.75
Quick Ratio
0.75

Sales & Book Value

Annual Sales
$121 thousand
Price / Sales
58.21
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.20 per share
Price / Book
13.00

Miscellaneous

Outstanding Shares
2,709,000
Free Float
68,740,000
Market Cap
$7.04 million
Optionable
Not Optionable
Beta
0.98

Social Links

7 Stocks to Ride The A.I. Megaboom Cover
7 Stocks to Ride The A.I. Megaboom


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

This page (NYSE:AIM) was last updated on 9/13/2025 by MarketBeat.com Staff
From Our Partners
He Called Nvidia at $1.10. Now, He Says THIS Stock Will…
The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...
The Oxford Club | Sponsoredtc pixel
Why Trump’s “Smart Dollar” could rewrite the rules
MUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...
Stansberry Research | Sponsoredtc pixel
Trump's Law S.1582: $21T Dollar Revolution Coming
Do you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...
Brownstone Research | Sponsoredtc pixel
Forget AI Stocks — This Device Will REPLACE the Microchip
While everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...
Banyan Hill Publishing | Sponsoredtc pixel
Retire Comfortably with These New Monthly Income ETFs?
Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...
Investors Alley | Sponsoredtc pixel
INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off
Right now, we’re witnessing a monumental shift in the world.
Traders Agency | Sponsoredtc pixel
“Fed Proof” Your Bank Account with THESE 4 Simple Steps
Starting as soon as a few months from now, the United States government will make a sweeping change to bank ac...
Weiss Ratings | Sponsoredtc pixel
Forget Tesla — This Tiny AI Stock Is Musk’s Real Play
While Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...
Behind the Markets | Sponsoredtc pixel